These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32233478)

  • 1. Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation.
    Wei L; Wen W; Rao L; Huang Y; Lei M; Liu K; Hu S; Song R; Ren Y; Wan J
    J Chem Inf Model; 2020 Sep; 60(9):4388-4402. PubMed ID: 32233478
    [No Abstract]   [Full Text] [Related]  

  • 2. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy.
    Hoffer L; Saez-Ayala M; Horvath D; Varnek A; Morelli X; Roche P
    J Chem Inf Model; 2019 Apr; 59(4):1472-1485. PubMed ID: 30908019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantum mechanics-based scoring rationalizes the irreversible inactivation of parasitic Schistosoma mansoni cysteine peptidase by vinyl sulfone inhibitors.
    Fanfrlík J; Brahmkshatriya PS; Řezáč J; Jílková A; Horn M; Mareš M; Hobza P; Lepšík M
    J Phys Chem B; 2013 Dec; 117(48):14973-82. PubMed ID: 24195769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
    Park H; Bahn YJ; Ryu SE
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
    Huang Y; Wei L; Han X; Chen H; Ren Y; Xu Y; Song R; Rao L; Su C; Peng C; Feng L; Wan J
    Eur J Med Chem; 2019 Dec; 184():111749. PubMed ID: 31589992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for rational design of covalently interacting inhibitors.
    Schmidt TC; Welker A; Rieger M; Sahu PK; Sotriffer CA; Schirmeister T; Engels B
    Chemphyschem; 2014 Oct; 15(15):3226-35. PubMed ID: 25251382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring.
    Zhu K; Borrelli KW; Greenwood JR; Day T; Abel R; Farid RS; Harder E
    J Chem Inf Model; 2014 Jul; 54(7):1932-40. PubMed ID: 24916536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosted neural networks scoring functions for accurate ligand docking and ranking.
    Ashtawy HM; Mahapatra NR
    J Bioinform Comput Biol; 2018 Apr; 16(2):1850004. PubMed ID: 29495922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in de novo design strategy for practical lead identification.
    Honma T
    Med Res Rev; 2003 Sep; 23(5):606-32. PubMed ID: 12789688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing reaction-based de novo design using a multi-label reaction class recommender.
    Ghiandoni GM; Bodkin MJ; Chen B; Hristozov D; Wallace JEA; Webster J; Gillet VJ
    J Comput Aided Mol Des; 2020 Jul; 34(7):783-803. PubMed ID: 32112286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Insights for Drugs Developed for Phospholipase D Enzymes.
    Stieglitz KA
    Curr Drug Discov Technol; 2018; 15(2):81-93. PubMed ID: 28814238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
    Ni S; Yuan Y; Huang J; Mao X; Lv M; Zhu J; Shen X; Pei J; Lai L; Jiang H; Li J
    J Med Chem; 2009 Sep; 52(17):5295-8. PubMed ID: 19691347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inspired by Nature: The 3-Halo-4,5-dihydroisoxazole Moiety as a Novel Molecular Warhead for the Design of Covalent Inhibitors.
    Pinto A; Tamborini L; Cullia G; Conti P; De Micheli C
    ChemMedChem; 2016 Jan; 11(1):10-4. PubMed ID: 26607551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Merging allosteric and active site binding motifs: de novo generation of target selectivity and potency via natural-product-derived fragments.
    Lanz J; Riedl R
    ChemMedChem; 2015 Mar; 10(3):451-4. PubMed ID: 25487909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based virtual screening approach for discovery of covalently bound ligands.
    Toledo Warshaviak D; Golan G; Borrelli KW; Zhu K; Kalid O
    J Chem Inf Model; 2014 Jul; 54(7):1941-50. PubMed ID: 24932913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
    Heikkilä T; Thirumalairajan S; Davies M; Parsons MR; McConkey AG; Fishwick CW; Johnson AP
    Bioorg Med Chem Lett; 2006 Jan; 16(1):88-92. PubMed ID: 16236496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors.
    Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():47-58. PubMed ID: 26231707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling.
    Bjij I; Ramharack P; Khan S; Cherqaoui D; Soliman MES
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31466292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.